Response rates that have never been observed with any regimen for cisplatin-ineligible, locally advanced or metastatic urothelial cancer after prior PD-1/PD-L1 inhibitors were seen with the use of enfortumab vedotin (Padcev), according to results from the phase 2 EV-201 trial (NCT03219333) presented during the 2021 Genitourinary Cancers Symposium.1
EV-201 was a noncomparative study with 2 cohorts. Cohort 1 has been previously reported on and was the subject of accelerated approval by the FDA in December 2019.2
“What I’ll discuss today are data from cohort 2, which specifically focused on cisplatin-ineligible patients who received immunotherapy in the frontline setting, and who were ineligible for cisplatin-containing chemotherapy at the time of study enrollment,” Arjun V. Balar, MD, said during a presentation of the data.
Cisplatin-based chemotherapy is considered the standard of…
